Evaluation of NICE's 1000th Technology Appraisal

In September, the National Institute for Health and Care Excellence (NICE) reached a significant milestone by publishing its 1000th Technology Appraisal in its 25^th anniversary year, TA1000: Iptacopan for treating paroxysmal nocturnal haemoglobinuria. The critical evaluation for this appraisal was conducted by the York Technology Assessment Review (TAR) Group from the Centre for Reviews and Dissemination (CRD) and the Centre for Health Economics (CHE) at the University of York, leading to a positive recommendation for the first oral treatment for this rare blood disorder.

Since NICE’s inception 25 years ago, the York TAR group has been at the forefront supporting the role of NICE in improving outcomes for people using the NHS and other public health and social care services by ensuring national guidance is underpinned by rigorous and independent assessments of clinical effectiveness and value for money.

Professor Claire Rothery, who led the evaluation for the 1000^th Technology Appraisal, said: “It is a huge honour to be part of such a significant milestone for NICE Technology Appraisals. We understand the critical role that TAR appraisals play in informing NICE decision-making, and we value the opportunity to contribute to shaping these decisions, improving outcomes for patients and maximising value to the NHS.”